Molina Healthcare (MOH) PT Lowered to $124 by Goldman Sachs Following Q4 Earnings Miss

Molina Healthcare Inc. (NYSE:MOH) is one of the most undervalued mid cap stocks to buy now. On February 12, Goldman Sachs lowered its price target on Molina Healthcare to $124 from $167 while keeping a Neutral rating. This adjustment was made following the company’s Q4 2025 earnings miss.

The firm noted that the return profiles for even the strongest operators in low-margin, government-priced cyclical businesses can diminish rapidly during a broad-based downturn. Goldman Sachs expects these challenges to persist, reflecting the sensitivity of managed care organizations to the current cyclical environment.

Earlier on February 9, UBS analyst AJ Rice lowered the firm’s price target on Molina Healthcare Inc. (NYSE:MOH) to $145 from $170 while maintaining a Neutral rating. AJ Rice noted that the backdrop for Medicaid and exchanges remains challenged.

Copyright: andreypopov / 123RF Stock Photo

Molina Healthcare Inc. (NYSE:MOH) provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces in the US. It operates in four segments: Medicaid, Medicare, Marketplace, and Other.

While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.